Insulin resistance – Diabetes
Diabetes mellitus is a chronic metabolic disorder, caused by a failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin. The World Health Organization estimates that 346 million people worldwide have diabetes.
Type 2 diabetes and its complications such as diabetic neuropathy, retinopathy and macrovascular complications (cardiovascular disease and stroke) have a significant economic impact on both the developed and emerging countries worldwide.
Lipid, lipoprotein and glucose metabolic disorders are interconnected and cause several human diseases. This underlines the importance of being able to measure both direct and indirect effects of medicines in integrated animal models and/or panels of complementary models of glucose, lipid and lipoprotein disturbances.
- Outstanding scientific expertise and consultancy
- Innovative in-house diet-induced animal models
- Gold-standard methods (euglycemic hyperinsulinemic clamp, hyperglycemic clamp) and novel in-house techniques
- Dedicated research platform to evaluate the therapeutic potential of your compounds in type 2 diabetes, as well as other metabolic disorders and cardiovascular complications
- Customized research solutions to target your needs
Animal Experimental Models
Nutrional animal models
Differentiate your incretin-based therapies and SGLT2 inhibitors in DIO mice
High fat diet CETP-apoB100 mouse
Diet Induced Obesity (DIO) rat (40% fat)
Insulin Resistant and dyslipidemic hamster model
Insulin Resistant rat
Genetic animal models
A leptin-deficient mouse model to study diabetes, obesity and diabetic dyslipidemia.
Zucker Diabetic Fatty (ZDF) rat
A genetic rat model for the study of type 2 diabetes, hyperglycemia, insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia and cardiovascular or renal complications.
Zucker fatty rat
A genetic rat model of obesity, insulin resistance and hypertension.
Goto-Kakizaki (GK) rat
A non-obese rat model for type 2 diabetes. A high fat diet can modulate the phenotype.
Technical platform / Read-Outs
|In vivo screening and profiling|
|Glucose tolerance test – GTT||Yes|
|Insulin tolerance test – ITT||Yes|
|Euglycemic hyperinsulinemic clamp||Gold-standard method|
|Hyperglycemic clamp||Gold-standard method|
|Whole body glucose turnover||Yes|
|In vivo individual tissue glucose uptake||Gold-standard method|
|Lipid tolerance test||Yes|
|Whole body FFA turnover||Gold-standard method|
|In vivo individual tissue FFA storage rate||Gold-standard method|
|Lipogenesis in vivo||Yes|
|In vivo Lipid cardiac metabolism||Yes|
|In vivo Glucose cardiac metabolism||Yes|
|Biochemistry / Biomarkers, Cardiometabolic parameters and other services|
|Biochemistry / Biomarkers||Yes|
|Basic services||Body weight, Food intake, Lipid homeostasis, Blood collection and tissue harvesting|
|Non invasive imaging services|
|Preclinical nuclear imaging services||Benefit of unique imaging services with innovative translational tracers associated with gamma imager, nanoSPECT/CT, nanoPET/CT, ultrasound imaging devices|